| 000 | 01895 a2200529 4500 | ||
|---|---|---|---|
| 005 | 20250517042620.0 | ||
| 264 | 0 | _c20151116 | |
| 008 | 201511s 0 0 eng d | ||
| 022 | _a1520-4804 | ||
| 024 | 7 |
_a10.1021/acs.jmedchem.5b00810 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aHolzer, Philipp | |
| 245 | 0 | 0 |
_aDiscovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors. _h[electronic resource] |
| 260 |
_bJournal of medicinal chemistry _cAug 2015 |
||
| 300 |
_a6348-58 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xchemical synthesis |
| 650 | 0 | 4 | _aCell Line, Tumor |
| 650 | 0 | 4 | _aClinical Trials, Phase I as Topic |
| 650 | 0 | 4 | _aDrug Discovery |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aIsoquinolines _xchemical synthesis |
| 650 | 0 | 4 |
_aPiperazines _xchemical synthesis |
| 650 | 0 | 4 |
_aProto-Oncogene Proteins c-mdm2 _xantagonists & inhibitors |
| 650 | 0 | 4 | _aRats |
| 650 | 0 | 4 | _aStructure-Activity Relationship |
| 650 | 0 | 4 |
_aTumor Suppressor Protein p53 _xgenetics |
| 650 | 0 | 4 | _aXenograft Model Antitumor Assays |
| 700 | 1 | _aMasuya, Keiichi | |
| 700 | 1 | _aFuret, Pascal | |
| 700 | 1 | _aKallen, Joerg | |
| 700 | 1 | _aValat-Stachyra, Therese | |
| 700 | 1 | _aFerretti, Stéphane | |
| 700 | 1 | _aBerghausen, Joerg | |
| 700 | 1 | _aBouisset-Leonard, Michèle | |
| 700 | 1 | _aBuschmann, Nicole | |
| 700 | 1 | _aPissot-Soldermann, Carole | |
| 700 | 1 | _aRynn, Caroline | |
| 700 | 1 | _aRuetz, Stephan | |
| 700 | 1 | _aStutz, Stefan | |
| 700 | 1 | _aChène, Patrick | |
| 700 | 1 | _aJeay, Sébastien | |
| 700 | 1 | _aGessier, Francois | |
| 773 | 0 |
_tJournal of medicinal chemistry _gvol. 58 _gno. 16 _gp. 6348-58 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1021/acs.jmedchem.5b00810 _zAvailable from publisher's website |
| 999 |
_c25081152 _d25081152 |
||